Analysis of CYP2A contributions to metabolism of 4-(methylnitrosamino)-1- (3-pyridyl)-1-butanone in human peripheral lung microsomes

Drug Metabolism and Disposition

Volumn 35, Issue 11, 2007, Pages 2086-2094

  Brown, Pamela J ^a   Bedard, Leanne L ^a   Reid, Ken R ^a   Petsikas, Dimitri ^a   Massey, Thomas E ^a  

^a QUEEN S UNIVERSITY   (Canada)

Author keywords

[No Author keywords available]

Indexed keywords

4 (METHYLNITROSAMINO) 1 (3 PYRIDYL) 1 BUTANONE; CYP2A13; CYTOCHROME P450 2A; UNCLASSIFIED DRUG;

ADULT; AGED; ARTICLE; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG METABOLISM; DRUG STRUCTURE; ENZYME ACTIVITY; FEMALE; GENETIC POLYMORPHISM; HUMAN; HUMAN TISSUE; MALE; PRIORITY JOURNAL;

AGED; ARYL HYDROCARBON HYDROXYLASES; BIOTRANSFORMATION; FEMALE; GENE EXPRESSION; GENOTYPE; GLYCOLS; HUMANS; HYDROXY ACIDS; HYDROXYLATION; KETO ACIDS; LUNG; MALE; MICROSOMES; MIDDLE AGED; MIXED FUNCTION OXYGENASES; MOLECULAR STRUCTURE; NITROSAMINES; OXIDATION-REDUCTION; POLYMORPHISM, SINGLE NUCLEOTIDE; PYRIDINES; SMOKING; STEROID HYDROXYLASES;

EID: 35548981762     PISSN: 00909556     EISSN: 1521009X     Source Type: Journal    
DOI: 10.1124/dmd.107.017343     Document Type: Article

References (34)

1. Bedard LL, Smith GBJ, Reid K, Petsikas D, and Massey TE (2002) Investigation of the role of lipoxygenase in bioactivation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in human lung. Chem Res Toxicol 15:1267-1273.
2. Breyer-Pfaff U, Martin HJ, Ernst M, and Maser E (2004) Enantioselectivity of carbonyl reduction of 4-methylnitrosamino-1-(3-pyridyl)-1-butanone by tissue fractions from human and rat and by enzymes isolated from human liver. Drug Metab Dispos 32:915-922.
3. Day KC, Plopper CG, and Fanucchi MV (2006) Age-specific pulmonary cytochrome P-450 3A1 expression in postnatal and adult rats. Am J Physiol Lung Cell Mol Physiol 291:L75-L83.
4. 6-methylguanine DNA adduct levels and Ki-ras activation in lung tumors from resistant and susceptible mouse strains. Mol Carcinog 8:177-185.
5. 1 in human lung. Carcinogenesis 17:2487-2494.
6. Fernandez-Salguero P and Gonzalez FJ (1995) The CYP2A gene subfamily: species differences, regulation, catalytic activities and role in chemical carcinogenesis. Pharmacogenetics 5:S123-S128.
7. Fukami T, Nakajima M, Sakai H, Katoh M, and Yokoi T (2007) CYP2A13 metabolizes the substrates of human CYP1A2, phenacetin, and theophylline. Drug Metab Dispos 35:335-339.
8. Hecht SS (1998) Biochemistry, biology, and carcinogenicity of tobacco-specific N-nitrosamines. Chem Res Toxicol 11:559-603.
9. Hecht SS (1999) DNA adduct formation from tobacco-specific N-nitrosamines. Mutat Res 424:127-142.
10. Hecht SS (2003) Tobacco carcinogens, their biomarkers and tobacco-induced cancer. Nat Rev Cancer 3:733-744.
11. Hoffmann D, Rivenson A, and Hecht SS (1996) The biological significance of tobacco-specific N-nitrosamines: smoking and adenocarcinoma of the lung. Crit Rev Toxicol 26:199-211.
12. Jalas JR, Ding X, and Murphy SE (2003) Comparative metabolism of the tobacco-specific nitrosamines 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone and 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanol by rat cytochrome P450 2A3 and human cytochrome P450 2A13. Drug Metab Dispos 31:1199-1202.
13. Lowry OH, Rosebrough NJ, Farr AL, and Randall RJ (1951) Protein measurement with the Folin phenol reagent. J Biol Chem 193:265-275.
14. Maser E, Stinner B, and Atalla A (2000) Carbonyl reduction of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) by cytosolic enzymes in human liver and lung. Cancer Lett 148:135-144.
15. McLemore TL, Adelberg S, Liu MC, McMahon NA, Yu SJ, Hubbard WC, Czerwinski M, Wood TG, Storeng R, Lubet RA, et al. (1990) Expression of CYP1A1 gene in patients with lung cancer: evidence for cigarette smoke-induced gene expression in normal lung tissue and for altered gene regulation in primary pulmonary carcinomas. J Natl Cancer Inst 82:1333-1339.
16. Messina ES, Tyndale RF, and Sellers EM (1997) A major role for CYP2A6 in nicotine C-oxidation by human liver microsomes. J Pharmacol Exp Ther 282:1608-1614.
17. Miyamoto M, Umetsu Y, Dosaka-Akita H, Sawamura Y, Yokota J, Kunitoh H, Nemoto N, Sato K, Ariyoshi N, and Kamataki T (1999) CYP2A6 gene deletion reduces susceptibility to lung cancer. Biochem Biophys Res Commun 261:658-660.
18. Patten CJ, Smith TJ, Murphy SE, Wang M-H, Lee J, Tynes RE, Koch P, and Yang CS (1996) Kinetic analysis of the activation of 4-(methylnitrosamino)-1-(3- pyridyl)-1-butanone by heterologously expressed human P450 enzymes and the effect of P450-specific chemical inhibitors on this activation in human liver microsomes. Arch Biochem Biophys 333:127-138.
19. Raunio H, Rautio A, Gullsten H, and Pelkonen O (2001) Polymorphisms of CYP2A6 and its practical consequences. Br J Clin Pharmacol 52:357-363.
20. Smith GBJ, Bend JR, Bedard LL, Reid KR, Petsikas D, and Massey TE (2003) Biotransformation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in peripheral human lung microsomes. Drug Metab Dispos 31:1134-1141.
21. Smith GBJ, Castonguay A, Donnelly PJ, Reid KR, Petsikas D, and Massey TE (1999) Biotransformation of the tobacco-specific carcinogen 4- (methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in freshly isolated human lung cells. Carcinogenesis 20:1809-1818.
22. Smith TJ, Guo Z, Gonzalez FJ, Guengerich FP, Stoner GD, and Yang CS (1992) Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone in human lung and liver microsomes and cytochromes P-450 expressed in hepatoma cells. Cancer Res 52:1757-1763.
23. Smith TJ, Guo Z, Guengerich FP, and Yang CS (1996) Metabolism of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) by human cytochrome P450 1A2 and its inhibition by phenethyl isothiocyanate. Carcinogenesis 17:809-813.
24. Smith TJ, Stoner GD, and Yang CS (1995) Activation of 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone (NNK) in human lung microsomes by cytochromes P450, lipoxygenase, and hydroperoxides. Cancer Res 55:5566-5573.
25. Su T, Bao Z, Zhang QY, Smith TJ, Hong JY, and Ding X (2000) Human cytochrome P450 CYP2A13: predominant expression in the respiratory tract and its high efficiency metabolic activation of a tobacco-specific carcinogen, 4-(methylnitrosamino)-1-(3-pyridyl)-1- butanone. Cancer Res 60:5074-5079.
26. Thun MJ, Lally CA, Flannery JT, Calle EE, Flanders WD, and Heath CW Jr (1997) Cigarette smoking and changes in the histopathology of lung cancer. J Natl Cancer Inst 89:1580-1586.
27. von Weymarn LB, Brown KM, and Murphy SE (2006) Inactivation of CYP2A6 and CYP2A13 during nicotine metabolism. J Pharmacol Exp Ther 316:295-303.
28. von Weymarn LB, Zhang QY, Ding X, and Hollenberg PF (2005) Effects of 8-methoxypsoralen on cytochrome P450 2A13. Carcinogenesis 26:621-629.
29. Wang H, Tan W, Hao B, Miao X, Zhou G, He F, and Lin D (2003) Substantial reduction in risk of lung adenocarcinoma associated with genetic polymorphism in CYP2A13, the most active cytochrome P450 for the metabolic activation of tobacco-specific carcinogen NNK. Cancer Res 63:8057-8061.
30. Wei C, Caccavale KJ, Kenhoe JJ, Thomas PE, and Iba MM (2001) CYP1A2 is expressed along with CYP1A1 in human lung. Cancer Lett 171:113-120.
31. Wong HL, Zhang X, Zhang QY, Gu J, Ding X, Hecht SS, and Murphy SE (2005) Metabolic activation of the tobacco carcinogen 4-(methylnitrosamino)-(3-pyridyl) -1-butanone by cytochrome P450 2A13 in human fetal nasal microsomes. Chem Res Toxicol 18:913-918.
32. Yamazaki H, Inui Y, Yun CH, Guengerich FP, and Shimada T (1992) Cytochrome P450 2e1 and 2a6 enzymes as major catalysts for metabolic activation of n-nitrosodialkylamines and tobacco-related nitrosamines in human liver microsomes. Carcinogenesis 13:1789-1794.
33. Zhang X, Su T, Zhang QY, Gu J, Caggana M, Li H, and Ding X (2002) Genetic polymorphisms of the human CYP2A13 gene: identification of single-nucleotide polymorphisms and functional characterization of an Arg257Cys variant. J Pharmacol Exp Ther 302:416-423.
34. Zhu LR, Thomas PE, Lu G, Reuhl KR, Yang GY, Wang LD, Wang SL, Yang CS, He XY, and Hong JY (2006) CYP2A13 in human respiratory tissues and lung cancers: an immunohistochemical study with a new peptide-specific antibody. Drug Metab Dispos 34:1672-1676.